Cancer and malaria are two major diseases, which have devastating effects on public health systems. In a quest
of developing new anticancer and antimalarial agents, a series of 22 unsymmetrical C5-curcumionds was synthesized and
evaluated for their anticancer activity against HeLa, KB, PC3 and DU145 cancer cell lines. Out of these, four compounds
displayed potent activity in HeLa cancer cell line (IC50 ranging from 0.7 to 0.9 µM) than standard FDA-approved drug
doxorubicin (IC50 = 1.7 µM). They also showed weak to moderate activity against other cancer cell lines. Unsymmetrical
C5-curcumionids were also evaluated for their antimalarial activity against CQ-sensitive and CQ-resistant strains of P.
falciparum. Weak antimalarial activities were observed with some compounds without any toxicity towards the mammalian
cell line at the highest tested concentration of 10 µM.
Keywords: Anticancer activity, Antimalarial activity, Curcumin, C5-curcuminoids, HeLa cancer cell line, Plasmodium falciparum.
Rights & PermissionsPrintExport